{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T20:47:38Z","timestamp":1761598058140},"reference-count":103,"publisher":"Informa UK Limited","issue":"5","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Hematology"],"published-print":{"date-parts":[[2019,5,4]]},"DOI":"10.1080\/17474086.2019.1597703","type":"journal-article","created":{"date-parts":[[2019,3,27]],"date-time":"2019-03-27T23:28:33Z","timestamp":1553729313000},"page":"273-284","update-policy":"http:\/\/dx.doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":3,"title":["Ibrutinib for the treatment of chronic lymphocytic leukemia"],"prefix":"10.1080","volume":"12","author":[{"given":"Marina","family":"Deodato","sequence":"first","affiliation":[{"name":"Department of Hematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Maria","family":"Frustaci","sequence":"additional","affiliation":[{"name":"Department of Hematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Zamprogna","sequence":"additional","affiliation":[{"name":"Department of Hematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Cairoli","sequence":"additional","affiliation":[{"name":"Department of Hematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Montillo","sequence":"additional","affiliation":[{"name":"Department of Hematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Tedeschi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2019,4,11]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21387"},{"key":"CIT0002","first-page":"4","volume":"6","author":"Rai KR.","year":"2008","journal-title":"Clin Adv Hematol Oncol"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24282"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-09-667675"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-05-647925"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.957203"},{"key":"CIT0007","unstructured":"Pazdur R. New drug application approval\u2014Imbruvica. Department of Health and Human Services. Food and Drug administration. (Ref ID 3395788); 2013"},{"key":"CIT0008","unstructured":"AbbVie.com [Internet]. Chicago (IL): AbbVie Inc; 2019. U.S. FDA Expands IMBRUVICA\u00ae (ibrutinib) Label to Include Overall Survival Data in Previously Untreated Chronic Lymphocytic Leukemia (CLL) and New Indication for Small Lymphocytic Lymphoma (SLL) Patients. 2016 May 9 [cited 2019 Mar 26]. Available from: https:\/\/news.abbvie.com\/news\/us-fda-expands-imbruvica-ibrutinib-label-to-include-overall-survival-data-in-previously-untreated-chronic-lymphocytic-leukemia-cll-and-new-indication-for-small-lymphocytic-lymphoma-sll-patients.htm"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.3109\/08830180109045584"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.iy.10.040192.000525"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2009.00836.x"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1038\/nri1808"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.21.120601.141018"},{"key":"CIT0014","doi-asserted-by":"crossref","unstructured":"Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.\u00a0Proc Natl Acad Sci U S A.\u00a02010;107:13075\u201313080.","DOI":"10.1073\/pnas.1004594107"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-6-59"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.358"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.7906"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215637"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-507947"},{"key":"CIT0020","doi-asserted-by":"crossref","first-page":"69760","DOI":"10.18632\/oncotarget.11951","volume":"7","author":"Wang A","year":"2016","journal-title":"Oncotarget"},{"key":"CIT0021","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-06-583294"},{"key":"CIT0022","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-328484"},{"key":"CIT0023","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-386417"},{"key":"CIT0024","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1004594107"},{"key":"CIT0025","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-01-547869"},{"key":"CIT0026","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.107011"},{"key":"CIT0027","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.114.060061"},{"key":"CIT0028","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.156"},{"key":"CIT0029","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-10-810044"},{"key":"CIT0030","volume-title":"Abstract presented at: 60th ASH Annual Meeting & Exposition","author":"Byrd JC","year":"2018"},{"key":"CIT0031","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1400376"},{"key":"CIT0032","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.175"},{"key":"CIT0033","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71182-9"},{"key":"CIT0034","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30212-1"},{"key":"CIT0035","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15421"},{"key":"CIT0036","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-09-527853"},{"key":"CIT0037","first-page":"185","volume":"16","author":"Korycka-Wo\u0142owiec A","year":"2017","journal-title":"Expert Opin Drug Saf"},{"key":"CIT0038","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-06-651125"},{"key":"CIT0039","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70335-3"},{"key":"CIT0040","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-12-617522"},{"key":"CIT0041","doi-asserted-by":"crossref","unstructured":"Burger JA, Sivina M, Jain N, et al. Randomized trial of ibrutinib versus ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. Blood.\u00a02019;133:1011\u20131019.","DOI":"10.1182\/blood-2018-10-879429"},{"key":"CIT0042","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00465-9"},{"key":"CIT0043","author":"Fraser G","year":"2018","journal-title":"Leukemia"},{"key":"CIT0044","unstructured":"Imbruvica.com [Internet]. Sunnyvale (CA); Pharmacyclics LLC; 2019. Imbruvica [prescribing information]. 2019 Jan [cited 2019 Mar 26]. Available from: https:\/\/www.imbruvica.com\/prescribing-information."},{"key":"CIT0045","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70513-8"},{"key":"CIT0046","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509388"},{"key":"CIT0047","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.192328"},{"key":"CIT0048","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812836"},{"key":"CIT0049","doi-asserted-by":"crossref","unstructured":"Moreno C, Greil R, Demirkan F, et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol.\u00a02019;20:43\u201356.","DOI":"10.1016\/S1470-2045(18)30788-5"},{"key":"CIT0050","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1313984"},{"key":"CIT0051","volume-title":"Abstract presented at: 60th ASH Annual Meeting & Exposition","author":"Shanafelt TD","year":"2018"},{"key":"CIT0052","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-10-606038"},{"key":"CIT0053","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-04-639203"},{"key":"CIT0054","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00667-4"},{"key":"CIT0055","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14324"},{"key":"CIT0056","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-10-604272"},{"key":"CIT0057","doi-asserted-by":"publisher","DOI":"10.1111\/sji.12333"},{"key":"CIT0058","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-621466"},{"key":"CIT0059","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-712828"},{"key":"CIT0060","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2016.1257795"},{"key":"CIT0061","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.171041"},{"key":"CIT0062","first-page":"970","volume":"30","author":"Vrontikis A","year":"2016","journal-title":"Oncology"},{"key":"CIT0063","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw210"},{"key":"CIT0064","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-04-1142"},{"key":"CIT0065","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.00325.2015"},{"key":"CIT0066","first-page":"1663","volume":"95","author":"Oda A","year":"2000","journal-title":"Blood"},{"key":"CIT0067","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-01-011817"},{"key":"CIT0068","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2006.01806.x"},{"key":"CIT0069","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.115.306130"},{"key":"CIT0070","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15080"},{"key":"CIT0071","doi-asserted-by":"crossref","unstructured":"Brown JR, Moslehi J, Ewer MS, et al. Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: an integrated analysis. Br J Haematol.\u00a02019;184:558\u2013569.","DOI":"10.1111\/bjh.15690"},{"key":"CIT0072","doi-asserted-by":"publisher","DOI":"10.3109\/10428199409056283"},{"key":"CIT0073","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24890"},{"key":"CIT0074","doi-asserted-by":"crossref","unstructured":"Messina JA, Maziarz EK, Spec A, et al. Disseminated cryptococcosis with brain involvement in patients with chronic lymphoid malignancies on ibrutinib. Open Forum Infect Dis.\u00a02017;4:ofw261.","DOI":"10.1093\/ofid\/ofw261"},{"key":"CIT0075","first-page":"27","volume":"21","author":"Arthurs B","year":"2017","journal-title":"Respir Med Case Rep"},{"key":"CIT0076","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1320710"},{"key":"CIT0077","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-2944-7"},{"key":"CIT0078","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-06-722991"},{"key":"CIT0079","doi-asserted-by":"publisher","DOI":"10.1186\/ar3400"},{"key":"CIT0080","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2018.03.004"},{"key":"CIT0081","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1182\/blood.V130.Suppl_1.830.830","volume":"130","author":"Rogers KA","year":"2017","journal-title":"Blood"},{"key":"CIT0082","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13020"},{"key":"CIT0083","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13098"},{"key":"CIT0084","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24773"},{"key":"CIT0085","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.147900"},{"key":"CIT0086","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.182907"},{"key":"CIT0087","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.198820"},{"key":"CIT0088","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1402716"},{"key":"CIT0089","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1400029"},{"key":"CIT0090","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29566"},{"key":"CIT0091","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-02-626846"},{"key":"CIT0092","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11589"},{"key":"CIT0093","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-05-2013"},{"key":"CIT0094","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2014.04.005"},{"key":"CIT0095","doi-asserted-by":"publisher","DOI":"10.1006\/geno.1997.4767"},{"key":"CIT0096","unstructured":"AbbVie.com [Internet]. Chicago (IL): AbbVie Inc; 2019. U.S. and European Regulators Accept Applications for AbbVie's Venetoclax, the First Potential BCL-2 Inhibitor for Chronic Lymphocytic Leukemia. 2016 Jan 12 [cited 2019 Mar 26]. Available from: https:\/\/news.abbvie.com\/news\/us-and-european-regulators-accept-applications-for-abbvies-venetoclax-first-potential-bcl-2-inhibitor-for-chronic-lymphocytic-leukemia.htm"},{"key":"CIT0097","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713976"},{"key":"CIT0098","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx031"},{"key":"CIT0099","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.32"},{"key":"CIT0100","volume-title":"Abstract presented at: 60th ASH Annual Meeting & Exposition","author":"Hillmen P","year":"2018"},{"key":"CIT0101","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.7502"},{"key":"CIT0102","volume-title":"Abstract presented at: 59th ASH Annual Meeting & Exposition","author":"Davids MS","year":"2017"},{"key":"CIT0103","volume-title":"Abstract presented at: 60th ASH Annual Meeting & Exposition","author":"Jain N","year":"2018"}],"container-title":["Expert Review of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17474086.2019.1597703","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T14:17:03Z","timestamp":1663165023000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17474086.2019.1597703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,11]]},"references-count":103,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5,4]]}},"alternative-id":["10.1080\/17474086.2019.1597703"],"URL":"https:\/\/doi.org\/10.1080\/17474086.2019.1597703","relation":{},"ISSN":["1747-4086","1747-4094"],"issn-type":[{"value":"1747-4086","type":"print"},{"value":"1747-4094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,11]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2019-01-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}